CDH2 and breast cancer: In the current work we hypothesized that using multiple markers described above will allow us to capture a wide range of CTCs using general breast cancer markers—MGB1, HER2 as well as epithelial (CK19, CDH1) and mesenchymal markers (VIM, CDH2, PLS3) for CTCs’ EMT phenotype determination.